➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
AstraZeneca
Harvard Business School
Medtronic
Moodys

Last Updated: January 18, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Tradipitant

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Tradipitant?

Tradipitant is an investigational drug.

There have been 8 clinical trials for Tradipitant. The most recent clinical trial was a Phase 1 trial, which was initiated on June 1st 2018.

The most common disease conditions in clinical trials are Dermatitis, Atopic, Dermatitis, and Eczema. The leading clinical trial sponsors are Vanda Pharmaceuticals, Cross Research S.A., and [disabled in preview].

There are eight US patents protecting this investigational drug and one hundred and thirty-one international patents.

Recent Clinical Trials for Tradipitant
TitleSponsorPhase
COVIDL1: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 InfectionVanda PharmaceuticalsPhase 3
Motion Syros: A Randomized Study Investigating the Efficacy of Tradipitant in Treating Motion SicknessVanda PharmaceuticalsPhase 3
Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE 2)Vanda PharmaceuticalsPhase 3

See all Tradipitant clinical trials

Clinical Trial Summary for Tradipitant

Top disease conditions for Tradipitant
Top clinical trial sponsors for Tradipitant

See all Tradipitant clinical trials

US Patents for Tradipitant

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Tradipitant   Start Trial Intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4- -yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone ELI LILLY AND COMPANY (Indianapolis, IN)   Start Trial
Tradipitant   Start Trial Process development of a pyridine-containing NK-1 receptor antagonist ELI LILLY AND COMPANY (Indianapolis, IN)   Start Trial
Tradipitant   Start Trial Method of treatment with tradipitant VANDA PHARMACEUTICALS INC. (Washington, DC)   Start Trial
Tradipitant   Start Trial Triazole derivatives as tachykinin receptor antagonists Eli Lilly and Company (Indianapolis, IN)   Start Trial
Tradipitant   Start Trial Crystalline forms of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4- -yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone Eli Lilly and Company (Indianapolis, IN)   Start Trial
Tradipitant   Start Trial Intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4- -yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone Eli Lilly and Company (Indianapolis, IN)   Start Trial
Tradipitant   Start Trial Intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4- -yl]-pyridin-3-yl)-(2-chlorophenyl)-methanone Vanda Pharmaceuticals Inc. (Washington, DC)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Tradipitant

Drugname Country Document Number Estimated Expiration Related US Patent
Tradipitant Australia AU2007337255 2026-12-20   Start Trial
Tradipitant Brazil BRPI0721069 2026-12-20   Start Trial
Tradipitant Canada CA2671770 2026-12-20   Start Trial
Tradipitant China CN101568523 2026-12-20   Start Trial
Tradipitant Cyprus CY1115270 2026-12-20   Start Trial
Tradipitant Denmark DK2121610 2026-12-20   Start Trial
Tradipitant Eurasian Patent Organization EA200970604 2026-12-20   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
AstraZeneca
Harvard Business School
Medtronic
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.